Medway School of Pharmacy, Universities of Kent, Central Avenue, Kent ME4 4TB, UK.
Colloids Surf B Biointerfaces. 2013 Mar 1;103:189-99. doi: 10.1016/j.colsurfb.2012.10.023. Epub 2012 Nov 5.
Piroxicam is a non-steroidal anti-inflammatory drug that is characterised by low solubility and high permeability. In order to improve the drug dissolution rate, the co-grinding method was used as an approach to prepare piroxicam co-ground in the carriers such as glucosamine hydrochloride. As, this amino sugar (glucosamine HCl) has been shown to decrease pain and improve mobility in osteoarthritis in joints, therefore, the incorporation of glucosamine in piroxicam formulations would be expected to offer additional benefits to patients. The effect of the order of grinding on the dissolution of piroxicam was also investigated. Co-ground drug and glucosamine were prepared in different ratios using a ball mill. The samples were then subjected to different grinding times. In order to investigate the effect of the grinding process on the dissolution behaviour of piroxicam, the drug was ground separately in the absence of glucosamine. Mixtures of ground piroxicam and unground D-glucosamine HCl were prepared. Physical mixtures of piroxicam and glucosamine were also prepared for comparison. The properties of prepared co-ground systems and physical mixtures were studied using a dissolution tester, FTIR, SEM, XRPD and DSC. These results showed that the presence of glucosamine HCl can increase dissolution rate of piroxicam compared to pure piroxicam. Generally, all dissolution profiles showed the fastest dissolution rate when ground piroxicam was mixed with unground glucosamine. This was closely followed by the co-grinding of piroxicam with glucosamine where lower grinding times showed the fastest dissolution. The solid state studies showed that the grinding of piroxicam for longer times had no effect on polymorphic form of piroxicam, whereas mixtures of piroxicam-glucosamine ground for longer times (60 min) converted piroxicam polymorph II to polymorph I.
吡罗昔康是非甾体类抗炎药,其特点是低溶解度和高通透性。为了提高药物的溶解速率,采用共研磨法将吡罗昔康与载体如盐酸氨基葡萄糖共研磨。由于这种氨基糖(盐酸氨基葡萄糖)已被证明可减轻关节炎关节的疼痛并提高其活动能力,因此,预计将氨基葡萄糖纳入吡罗昔康制剂中会为患者带来额外的益处。还研究了研磨顺序对吡罗昔康溶解的影响。使用球磨机以不同比例将共研磨药物和氨基葡萄糖制备。然后将样品进行不同的研磨时间。为了研究研磨过程对吡罗昔康溶解行为的影响,将药物在没有氨基葡萄糖的情况下单独研磨。制备了研磨吡罗昔康和未研磨 D-氨基葡萄糖盐酸盐的混合物。还制备了吡罗昔康和氨基葡萄糖的物理混合物进行比较。使用溶解测试仪、FTIR、SEM、XRPD 和 DSC 研究了制备的共研磨系统和物理混合物的性质。这些结果表明,与纯吡罗昔康相比,盐酸氨基葡萄糖的存在可以提高吡罗昔康的溶解速率。通常,所有的溶解曲线都显示当研磨吡罗昔康与未研磨氨基葡萄糖混合时,具有最快的溶解速率。其次是吡罗昔康与氨基葡萄糖的共研磨,其中较低的研磨时间显示出最快的溶解。固态研究表明,较长时间的吡罗昔康研磨对吡罗昔康的多晶型形式没有影响,而较长时间(60 分钟)研磨的吡罗昔康-氨基葡萄糖混合物将吡罗昔康 II 型转化为 I 型。